Effect of Time Interval on the Outcome with Transarterial Chemoembolization Followed Microwave Ablation with Hepatocellular Carcinoma

Haiyan FU; Junfang YAN; Hongjuan LI; Lin WANG; Jie ZHANG; Yujun ZHOU; Bin XU; Yu LUO

doi:10.12259/j.issn.2095-610X.S20221127

Volume 43 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(11): 63-70

Haiyan FU, Junfang YAN, Hongjuan LI, Lin WANG, Jie ZHANG, Yujun ZHOU, Bin XU, Yu LUO. Effect of Time Interval on the Outcome with Transarterial Chemoembolization Followed Microwave Ablation with Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2022, 43(11): 63-70. doi: 10.12259/j.issn.2095-610X.S20221127

Citation:

Haiyan FU, Junfang YAN, Hongjuan LI, Lin WANG, Jie ZHANG, Yujun ZHOU, Bin XU, Yu LUO. Effect of Time Interval on the Outcome with Transarterial Chemoembolization Followed Microwave Ablation with Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2022, 43(11): 63-70. doi: 10.12259/j.issn.2095-610X.S20221127

Citation:

Haiyan FU, Junfang YAN, Hongjuan LI, Lin WANG, Jie ZHANG, Yujun ZHOU, Bin XU, Yu LUO. Effect of Time Interval on the Outcome with Transarterial Chemoembolization Followed Microwave Ablation with Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2022, 43(11): 63-70. doi: 10.12259/j.issn.2095-610X.S20221127

PDF( 1240 KB)

Effect of Time Interval on the Outcome with Transarterial Chemoembolization Followed Microwave Ablation with Hepatocellular Carcinoma

doi: 10.12259/j.issn.2095-610X.S20221127

1.
Dept. of Interventional Radiolology
2.
Dept. of Pathology，The 3rd People’s Hospital of Kunming，Kunming Yunnan 650500，China

Received Date: 2022-04-27
Available Online: 2022-07-20
Publish Date: 2022-11-14

Abstract

Abstract

Objective To analyse the effect of time interval on the outcome of microwave ablation （MWA）treatment of hepatocellular carcinoma （HCC） after transarterial chemoembolization （TACE）. Methods A retrospective analysis of recurrent 71 HCC patients after receiving TACE and MWA at the 3^rd People’s Hospital of Kunming from February 2016 to December 2018; with 32 patients received sequential MWA treatment within 4 weeks after TACE （sequential Treatment group）, and 39 patients received delayed MWA treatment （delayed Treatment group） 4 weeks after the completion of TACE, the overall survival （OS） and progression-free survival （PFS） of two groups were observed. Survival curve was plotted using Kaplan-Meier, the multiple Cox proportional hazard regression was used to analyze prognostic factors, compare adverse reactions between the two groups. Results The median OS of the sequential group and the delayed group were 35.3 months and 29.1 months, respectively. PFS in the sequential group was 27 months, and 13.8 months in the delayed group. The sequential group had better overall survival OS （HR, 0.601; 95%CI, 0.378-0.796; P = 0.037） and longer PFS （HR, 0.779; 95%CI, 0.415-0.821; P = 0.004）. Maximum tumor diameter, number of tumors, and time interval are factors that affect OS and PFS. Child-Pugh classification is a factor that affects OS but does not affect PFS. Conclusion TACE plus sequential MWA within 4 weeks was more effective for treatment HCC than delayed MWA, and does not increase adverse reactions.
- Hepatocellular carcinoma,
- Time interval,
- Transarterial chemoembolization,
- Microwave ablation

FullText(HTML)

References(27)

References

[1]	Sung H,Ferlay J,Siegel R L,et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
[2]	Cho J Y,Han H S,Choi Y,et al. Association of remnant liver ischemia with early recurrence and poor survival after liver resection in patients with hepatocellular carcinoma[J]. JAMA Surg,2017,152(4):1-7.
[3]	Marrer J A,Kulik L M,Sirlin C B,et al. Diagnosis,staging,and management of hepatocellular carcinoma:2018 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2018,68(2):723-750. doi: 10.1002/hep.29913
[4]	Omata M,Cheng A L,Kokudo N,et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A 2017 update[J]. Hepatol Int,2017,11(4):317-370. doi: 10.1007/s12072-017-9799-9
[5]	Chen Y P,Zhang J L,Zou Y,et al. Recent advances on polymeric beads or hydrogels as embolization agents forimproved transcatheter arterial ahemoembolization (TACE)[J]. Front Chem,2019,5(7):408.
[6]	Camma C,Schepis F,Orlando A,et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma:Meta-analysis of randomized controlled trials[J]. Radiology,2002,224(1):47-54. doi: 10.1148/radiol.2241011262
[7]	Izzo F,Granata V,Grassi R,et al. Radiofrequency ablation and microwave ablation in liver tumors:An update[J]. Oncologist,2019,24(10):990-1005. doi: 10.1634/theoncologist.2018-0337
[8]	Sheta E,Elkalla F,Elgharib M,et al. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma:A randomized-controlled study[J]. Eur J Gastroenterol Hepatol,2016,28(10):1198-1203. doi: 10.1097/MEG.0000000000000688
[9]	Schlachterman A,Craftww J R,Hilgendeldt E,et al. Current and future treatments for hepatocellular carcinoma[J]. World J Gastroenterol,2015,21(28):8478-8491. doi: 10.3748/wjg.v21.i28.8478
[10]	Lencioni R,Llovet J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin in Liver Dis,2010,30(1):52-60. doi: 10.1055/s-0030-1247132
[11]	王贵强,王福生,成军,等. 慢性乙型肝炎防治指南(2015更新版)[J]. 中华肝脏病杂志,2015,23(12):888-905. doi: 10.3760/cma.j.issn.1007-3418.2015.12.002
[12]	魏来,侯金林. 丙型肝炎防治指南(2015年更新版)[J]. 中华实验和临床感染病杂志(电子版),2015,9(5):590-607. doi: 10.3877/cma.j.issn.1674-1358.2015.05.002
[13]	Bodzin A S,Busuttil R W. Hepatocellular carcinoma:Advances in diagnosis,management,and long term outcome[J]. World J Hepatol,2015,7(9):1157-1167. doi: 10.4254/wjh.v7.i9.1157
[14]	Makary M S,Khandpur U,Cloyd J M,et al. Locoregional therapy approaches for hepatocellular carcinoma:Recent advances and management strategies[J]. Cancers (Basel),2020,12(7):1914. doi: 10.3390/cancers12071914
[15]	Zhu F,Rhim H. Thermal ablation for hepatocellular carcinoma:What's new in 2019[J]. Chin Clin Oncol,2019,8(6):58. doi: 10.21037/cco.2019.11.03
[16]	Dong B W,Zhang J,Liang P,et al. Sequential pathological and immunologic analysisof percutaneous microwave coagulation therapy of hepatocellular carcinoma[J]. Int J Hyperthermia,2003,19(2):119-133. doi: 10.1080/0265673021000017154
[17]	Guo H,Chen B,Li W,et al. Percutaneous microwave coagulation therapy:A promising therapeutic method for breaking the barrier of the intertumor heterogeneity[J]. J Healthc Eng,2021,11(19):7773163.
[18]	Zhang J,Dong B,Liang P,et al. Significance of changes in local immunity in patients with hepatocellular carcinoma after percutaneous microwave coagulation therapy[J]. Chin Med J (Engl),2002,115(9):1367-1371.
[19]	Zhang E L, Yang F, Wu Z B, et al, Therapeutic efficacy of percutaneous microwave coagulation versus liver resection for single hepatocellular carcinoma ≤3 cm with Child-Pugh A cirrhosis[J]. Eur J Surg Oncol, 2016, 42（5）: 690-697.
[20]	Li J,Tao H S,Li J,et al. Effect of severity of liver cirrhosis on surgical outcomes of hepatocellular carcinoma after liver resection and microwave coagulation[J]. Front Oncol,2021,6(11):745615.
[21]	Ryu T,Takmi Y,Wada Y,et al. Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma ≤5 cm:A propensity score-matched analysis[J]. Surgery,2019,166(3):254-262. doi: 10.1016/j.surg.2019.05.007
[22]	Lee S,Kang T W,Cha D I,et al. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma:Propensity score analyses of long-term outcomes[J]. J Hepatol,2018,69(1):70-78. doi: 10.1016/j.jhep.2018.02.026
[23]	Leung U,Kuk D,Dangelica M I,et al. Long-term outcomes following microwave ablation for liver malignancies[J]. Br J Surg,2015,102(1):85-91.
[24]	Zhang N N,Lu W,Cheng X J,et al. High-powered microwave ablation of larger hepatocellular carcinoma:Evaluation of recurrence rate and factors related to recurrence[J]. Clin Radiol,2015,70(11):1237-1243. doi: 10.1016/j.crad.2015.06.092
[25]	Zhang T T,Luo H C,Cui X,et al. Ultrasound-guided percutaneous microwave ablation treatment of initial recurrent hepatocellular carcinoma after hepatic resection:Long-term outcomes[J]. Ultrasound Med Biol,2015,41(9):2391-2399. doi: 10.1016/j.ultrasmedbio.2015.04.019
[26]	Dong Z R,Zhang P F,Wang C H,et al. Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria:A retrospective analysis[J]. Am J Cancer Res,2015,5(1):450-457.
[27]	Ke Q,Xiang F,Xiao C,et al. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization[J]. BMC Cancer,2021,21(1):1117. doi: 10.1186/s12885-021-08843-z

Relative Articles(20)

Relative Articles

[1]	Yixuan CHEN, Lin WANG, Xiuhong XIA, Zaikun PENG, Yi DING, Runjiao SHI, Xuefen LEI. Research Progress on the Mechanisms of Autophagy in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2023, 44(4): 159-164. doi: 10.12259/j.issn.2095-610X.S20230416
[2]	Ming ZHANG, Chenglong YU, Jinpeng CAO. ZNF384 Regulates Metastasis of Hepatocellular Carcinoma via GCLM. Journal of Kunming Medical University, 2023, 44(11): 56-62. doi: 10.12259/j.issn.2095-610X.S20231108
[3]	Heng ZHANG, Cheng ZHANG, Weiran LIAO, Yutao HE, Yuyang ZHANG, Bin DU, Lin WANG. Research Progress of Zinc Finger Protein and Hepatocellular Carcinoma. Journal of Kunming Medical University, 2022, 43(1): 144-149. doi: 10.12259/j.issn.2095-610X.S20220135
[4]	Tianhong ZHANG, Hongju YANG. Research Progress of Exosomal miRNA in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2022, 43(2): 150-153. doi: 10.12259/j.issn.2095-610X.S20220221
[5]	Fan CAO, Yang-wen LIU, Lei WEI, Nan XIE, Yi-jian YANG, Cheng QIAN, Chun-mang LI, Bi-mang FU, Jiang-pin XU, Rong-ji YAN, Wang ZENG. Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2021, 42(3): 127-134. doi: 10.12259/j.issn.2095-610X.S20210331
[6]	Xu Hai Xia , Li Xin Hong . . Journal of Kunming Medical University, 2020, 41(06): 132-135.
[7]	Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223
[8]	Gao Jing , Li Ying Hua , Yuan Yuan , Wu Shi Cong . . Journal of Kunming Medical University, 2019, 40(08): 78-82.
[9]	Tan Hua , Ren Hong , Zhao Ling , You Ding Yun , Yang Ya Chen . Prognostic Factors of Patients with Primary Hepatocellular Carcinoma Treated with TACE. Journal of Kunming Medical University, 2019, 40(03): 29-34.
[10]	Fan Xu , Feng Yu Ran , Zhu Mei . . Journal of Kunming Medical University, 2019, 40(11): 1-5.
[11]	Lei Xi Feng , Hou Feng Qiang , Liu Tao , Zhang Wei . . Journal of Kunming Medical University, 2018, 39(11): 11-15.
[12]	Lei Xi Feng , Hou Feng Qiang , Yang Shao Hua , Zhang Wei . . Journal of Kunming Medical University, 2018, 39(12): 49-53.
[13]	Tian Bo Yan , Yang Qin Ling , Zhang Jiao Qiong , Han Na , Liu Shao Hua . The Curative Effect of Auxiliary Hepatic Arterial Chemoembolization in the Treatment of Microvascular Invasion of Hepatocellular Carcinoma. Journal of Kunming Medical University, 2018, 39(08): 86-92.
[14]	Gao Jing Yan , Chen Fu Kun , Yan Jia Wen , Wang Jia Ping . Clinical Analysis of Transcatheter Arterial Chemoembolization Combined with Intensity Modulated Radiotherapy Therapy for Patients with Primary Hepatic Carcinoma. Journal of Kunming Medical University, 2017, 38(01): 95-98.
[15]	Hao Ying Lu . . Journal of Kunming Medical University,
[16]	Qiu Jian Wu . . Journal of Kunming Medical University,
[17]	Guo Xi . . Journal of Kunming Medical University,
[18]	Liu Hui Jin . . Journal of Kunming Medical University,
[19]	Yu Jie . . Journal of Kunming Medical University,
[20]	. Therapeutic Effects of CsA Combined with Hepatocyte Intrasplenic Transplantation on Acute Hepatic Failure. Journal of Kunming Medical University,